Author

Rishitha Nalabothu

Institution: Vanderbilt University Medical Center

Observed institutions: Vanderbilt University, Vanderbilt University Medical Center

OpenAlex ID: A5120733007

Overcoming toxicity challenges in immune checkpoint inhibitor treatment of high-risk metastatic cancers

2025 · Rishitha Nalabothu, Douglas B. Johnson · Expert Review of Anticancer Therapy · 1

ADAPT-M: A tool to predict individualized benefit from adjuvant anti–PD-1 (PD-1) in resected high-risk melanoma.

2026 · Ines Esteves Domingues Pires da Silva, Susana Puig, et al. · Journal of Clinical Oncology

Works count: 2

Citation count: 1

H-index: 1

I10-index: